P024 was a four-month, double-blind randomized trial that compared letrozole 2.5 mg with tamoxifen 20 mg in the preoperative treatment of 337 postmenopausal women who had ER+ locally advanced breast cancer and were ineligible for BCS. This evidence concerns the gene ESR1 and breast cancer.